Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Metabolic inflexibility in women with PCOS is similar to women with type 2 diabetes.

Broskey NT, Tam CS, Sutton EF, Altazan AD, Burton JH, Ravussin E, Redman LM.

Nutr Metab (Lond). 2018 Oct 20;15:75. doi: 10.1186/s12986-018-0312-9. eCollection 2018.

2.

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS.

J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359. [Epub ahead of print] No abstract available.

PMID:
30359156
3.

Skeletal muscle adiponectin induction depends on diet, muscle type/activity, and exercise modality in C57BL/6 mice.

Martinez-Huenchullan SF, Maharjan BR, Williams PF, Tam CS, Mclennan SV, Twigg SM.

Physiol Rep. 2018 Oct;6(20):e13848. doi: 10.14814/phy2.13848.

4.

The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL.

Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S.

Blood. 2018 Oct 4. pii: blood-2018-05-850461. doi: 10.1182/blood-2018-05-850461. [Epub ahead of print]

PMID:
30287523
5.

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C.

Am J Hematol. 2018 Nov;93(11):1394-1401. doi: 10.1002/ajh.25261. Epub 2018 Sep 26.

PMID:
30132965
6.

Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware.

Tam CS, Brown JR.

Leuk Lymphoma. 2018 Jul 22:1-2. doi: 10.1080/10428194.2018.1482546. [Epub ahead of print] No abstract available.

PMID:
30032684
7.

Point: Does Chemoimmunotherapy Still Have a Role in CLL? Chemoimmunotherapy With FCR Is Still an Important Option in CLL.

Thompson PA, Tam CS.

Oncology (Williston Park). 2018 Jun;32(6):291-2, 294-6. No abstract available.

8.

Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.

Agarwal R, Dawson MA, Dreyling M, Tam CS.

Leuk Lymphoma. 2018 Jun 18:1-13. doi: 10.1080/10428194.2018.1457148. [Epub ahead of print]

PMID:
29912596
9.

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.

Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C.

Future Oncol. 2018 Sep;14(22):2229-2237. doi: 10.2217/fon-2018-0163. Epub 2018 Jun 5.

10.

Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies.

Teh BW, Tam CS, Handunnetti S, Worth LJ, Slavin MA.

Blood Rev. 2018 Apr 23. pii: S0268-960X(17)30158-3. doi: 10.1016/j.blre.2018.04.007. [Epub ahead of print] Review.

PMID:
29709246
11.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW.

N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

12.

Differential metabolic effects of constant moderate versus high intensity interval training in high-fat fed mice: possible role of muscle adiponectin.

Martinez-Huenchullan SF, Maharjan BR, Williams PF, Tam CS, Mclennan SV, Twigg SM.

Physiol Rep. 2018 Feb;6(4). doi: 10.14814/phy2.13599.

13.

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia.

Othman J, Verner E, Tam CS, Huang J, Lin L, Hilger J, Trotman J, Gasiorowski R.

Haematologica. 2018 May;103(5):e223-e225. doi: 10.3324/haematol.2017.186817. Epub 2018 Feb 8. No abstract available.

14.

Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia.

Kuss BJ, Tam CS.

Intern Med J. 2017 Dec;47 Suppl 6:5-10. doi: 10.1111/imj.13680. Review.

PMID:
29250930
15.

Intramyocellular Lipid Droplet Size Rather Than Total Lipid Content is Related to Insulin Sensitivity After 8 Weeks of Overfeeding.

Covington JD, Johannsen DL, Coen PM, Burk DH, Obanda DN, Ebenezer PJ, Tam CS, Goodpaster BH, Ravussin E, Bajpeyi S.

Obesity (Silver Spring). 2017 Dec;25(12):2079-2087. doi: 10.1002/oby.21980. Epub 2017 Oct 25.

16.

Ibrutinib may impair serological responses to influenza vaccination.

Douglas AP, Trubiano JA, Barr I, Leung V, Slavin MA, Tam CS.

Haematologica. 2017 Oct;102(10):e397-e399. doi: 10.3324/haematol.2017.164285. Epub 2017 Jun 28. No abstract available.

17.

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC.

Leukemia. 2018 Jan;32(1):83-91. doi: 10.1038/leu.2017.175. Epub 2017 Jun 8.

18.

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.

Chai KL, Rowan G, Seymour JF, Burbury K, Carney D, Tam CS.

Leuk Lymphoma. 2017 Dec;58(12):2811-2814. doi: 10.1080/10428194.2017.1315115. Epub 2017 May 15. Review.

PMID:
28504030
19.

Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era.

Butler LA, Tam CS, Seymour JF.

Blood Rev. 2017 Sep;31(5):318-327. doi: 10.1016/j.blre.2017.05.002. Epub 2017 May 3. Review.

PMID:
28499646
20.

Utility and reliability of non-invasive muscle function tests in high-fat-fed mice.

Martinez-Huenchullan SF, McLennan SV, Ban LA, Morsch M, Twigg SM, Tam CS.

Exp Physiol. 2017 Jul 1;102(7):773-778. doi: 10.1113/EP086328. Epub 2017 Jun 1.

PMID:
28497900
21.

The emerging role of skeletal muscle extracellular matrix remodelling in obesity and exercise.

Martinez-Huenchullan S, McLennan SV, Verhoeven A, Twigg SM, Tam CS.

Obes Rev. 2017 Jul;18(7):776-790. doi: 10.1111/obr.12548. Epub 2017 May 5. Review.

PMID:
28474421
22.

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

Tam CS, Seymour JF.

Ann Oncol. 2017 May 1;28(5):920-921. doi: 10.1093/annonc/mdx103. No abstract available.

PMID:
28379289
23.

The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.

Kostos L, Chai KL, Tam CS, Bazargan A.

Leuk Lymphoma. 2017 Nov;58(11):2720-2723. doi: 10.1080/10428194.2017.1281414. Epub 2017 Mar 23. No abstract available.

PMID:
28332891
24.

Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.

Yeh P, Hunter T, Sinha D, Ftouni S, Wallach E, Jiang D, Chan YC, Wong SQ, Silva MJ, Vedururu R, Doig K, Lam E, Arnau GM, Semple T, Wall M, Zivanovic A, Agarwal R, Petrone P, Jones K, Westerman D, Blombery P, Seymour JF, Papenfuss AT, Dawson MA, Tam CS, Dawson SJ.

Nat Commun. 2017 Mar 17;8:14756. doi: 10.1038/ncomms14756.

25.

Microvesicles in chronic lymphocytic leukemia: ready for prime time in the clinic?

Handunnetti SM, Polliack A, Tam CS.

Leuk Lymphoma. 2017 Jun;58(6):1281-1282. doi: 10.1080/10428194.2017.1298756. No abstract available.

PMID:
28271951
26.

Novel agents versus chemotherapy as frontline treatment of CLL.

Piggin A, Bayly E, Tam CS.

Leuk Lymphoma. 2017 Jun;58(6):1320-1324. doi: 10.1080/10428194.2017.1280606. Epub 2017 Feb 6. Review.

PMID:
28271950
27.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.

Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.

28.

Skeletal muscle extracellular matrix remodeling after short-term overfeeding in healthy humans.

Tam CS, Chaudhuri R, Hutchison AT, Samocha-Bonet D, Heilbronn LK.

Metabolism. 2017 Feb;67:26-30. doi: 10.1016/j.metabol.2016.10.009. Epub 2016 Oct 28.

PMID:
28081775
29.

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM.

Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311.

PMID:
28076910
30.

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

Thompson PA, Lévy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, Dupuis J, Keating MJ, Meune C, Cymbalista F.

Br J Haematol. 2016 Nov;175(3):462-466. doi: 10.1111/bjh.14324. Epub 2016 Sep 9.

PMID:
27611233
31.

Does weight cycling promote obesity and metabolic risk factors?

Mackie GM, Samocha-Bonet D, Tam CS.

Obes Res Clin Pract. 2017 Mar - Apr;11(2):131-139. doi: 10.1016/j.orcp.2016.10.284. Epub 2016 Oct 20. Review.

PMID:
27773644
32.

Raised FGF-21 and Triglycerides Accompany Increased Energy Intake Driven by Protein Leverage in Lean, Healthy Individuals: A Randomised Trial.

Gosby AK, Lau NS, Tam CS, Iglesias MA, Morrison CD, Caterson ID, Brand-Miller J, Conigrave AD, Raubenheimer D, Simpson SJ.

PLoS One. 2016 Aug 18;11(8):e0161003. doi: 10.1371/journal.pone.0161003. eCollection 2016.

33.

Energy Metabolic Adaptation and Cardiometabolic Improvements One Year After Gastric Bypass, Sleeve Gastrectomy, and Gastric Band.

Tam CS, Redman LM, Greenway F, LeBlanc KA, Haussmann MG, Ravussin E.

J Clin Endocrinol Metab. 2016 Oct;101(10):3755-3764. Epub 2016 Aug 4.

PMID:
27490919
34.

High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.

Cheah CY, Joske D, Cull G, Gilbertson M, Opat SS, Tam CS, Wirth A, Seymour JF.

Br J Haematol. 2017 Sep;178(6):991-994. doi: 10.1111/bjh.14187. Epub 2016 Jul 29. No abstract available.

PMID:
27470657
35.

Maintenance therapy in CLL: resolving the controversy.

Tam CS.

Lancet Haematol. 2016 Jul;3(7):e304-5. doi: 10.1016/S2352-3026(16)30046-1. Epub 2016 Jun 16. No abstract available.

PMID:
27374461
36.

Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation.

Chan KL, Lokan J, Tam CS, Lew TE, Prince HM.

Leuk Lymphoma. 2017 Jan;58(1):207-210. Epub 2016 Jun 21. No abstract available.

PMID:
27326828
37.

Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.

Chan KL, Blombery P, Jones K, Lade S, Carney D, Tran H, Seymour JF, Tam CS.

Br J Haematol. 2017 Apr;177(2):324-328. doi: 10.1111/bjh.14062. Epub 2016 May 15. No abstract available.

PMID:
27196127
38.

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.

Tam CS, Seymour JF, Roberts AW.

Semin Oncol. 2016 Apr;43(2):274-9. doi: 10.1053/j.seminoncol.2016.02.014. Epub 2016 Feb 6. Review.

PMID:
27040706
39.

Mechanisms of metabolism, aging and obesity.

Floyd ZE, Gawronska-Kozak B, Tam CS, Gimble JM.

Biochimie. 2016 May;124:1-2. doi: 10.1016/j.biochi.2016.03.005. Epub 2016 Mar 17. No abstract available.

PMID:
26995405
40.

Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Tam CS, Kamel S.

Haematologica. 2016 Mar;101(3):e123. doi: 10.3324/haematol.2015.139030. No abstract available.

41.

Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.

Tam CS, Kimber T, Seymour JF.

Br J Haematol. 2017 Mar;176(5):829-831. doi: 10.1111/bjh.14000. Epub 2016 Feb 25. No abstract available.

PMID:
26915463
42.

Disseminated visceral varicella zoster virus presenting with the constellation of colonic pseudo-obstruction, acalculous cholecystitis and syndrome of inappropriate ADH secretion.

Braude MR, Trubiano JA, Heriot A, Dickinson M, Carney D, Seymour JF, Tam CS.

Intern Med J. 2016 Feb;46(2):238-9. doi: 10.1111/imj.12977. No abstract available.

PMID:
26899893
43.

Defining the appropriate starting dose of lenalidomide in chronic lymphocytic leukemia: remember the old fable of the hare and the tortoise.

Tam CS, Polliack A.

Leuk Lymphoma. 2016;57(6):1247-8. doi: 10.3109/10428194.2015.1137294. Epub 2016 Feb 17. No abstract available.

PMID:
26732524
44.

The effects of high-fat feeding on physical function and skeletal muscle extracellular matrix.

Tam CS, Power JE, Markovic TP, Yee C, Morsch M, McLennan SV, Twigg SM.

Nutr Diabetes. 2015 Dec 14;5:e187. doi: 10.1038/nutd.2015.39.

45.

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators.

N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.

46.

Energy Adaptations Persist 2 Years After Sleeve Gastrectomy and Gastric Bypass.

Tam CS, Rigas G, Heilbronn LK, Matisan T, Probst Y, Talbot M.

Obes Surg. 2016 Feb;26(2):459-63. doi: 10.1007/s11695-015-1972-4.

PMID:
26637359
47.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ.

Blood. 2016 Jan 21;127(3):303-9. doi: 10.1182/blood-2015-09-667675. Epub 2015 Oct 22.

48.

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy.

Lew TE, Cheah CY, Carney DA, Prince HM, Wolf M, Bazargan A, Januszewicz EH, Filshie R, Westerman D, Seymour JF, Tam CS.

Leuk Lymphoma. 2016 May;57(5):1044-53. doi: 10.3109/10428194.2015.1096353. Epub 2015 Nov 20.

PMID:
26464106
49.

Myokine Expression in Muscle and Myotubes in Response to Exercise Stimulation.

Covington JD, Tam CS, Bajpeyi S, Galgani JE, Noland RC, Smith SR, Redman LM, Ravussin E.

Med Sci Sports Exerc. 2016 Mar;48(3):384-90. doi: 10.1249/MSS.0000000000000787.

50.

A novel way to consolidate incomplete responses in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Tam CS, Polliack A.

Leuk Lymphoma. 2016;57(3):503-4. doi: 10.3109/10428194.2015.1096358. Epub 2015 Oct 15. No abstract available.

PMID:
26390065

Supplemental Content

Support Center